Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001193805-25-001205
Filing Date
2025-08-18
Accepted
2025-08-18 17:59:19
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 13815
2 e664792_ex99-a.htm EX-99.A 5069
3 e664792_ex99-b.htm EX-99.B 899
  Complete submission text file 0001193805-25-001205.txt   21359
Mailing Address 780 THIRD AVENUE 37TH FLOOR NEW YORK NY 10017
Business Address
Flynn James E (Filed by) CIK: 0001352546 (see all company filings)

Type: SCHEDULE 13G

Mailing Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080
Business Address 256 E. GRAND AVENUE, SUITE 104 SOUTH SAN FRANCISCO CA 94080 857 702 0377
BridgeBio Oncology Therapeutics, Inc. (Subject) CIK: 0001869105 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-94447 | Film No.: 251229081
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)